Skip to content
drillr.ai
Sign up

01530.HK

3SBio Inc.

HKSE · Healthcare · Biotechnology · CN

HKD 13.54
−1.53%
Ask drillr

  • Oct 12, 2026, 10:22 UTC

    3SBio, Inc. repurchased 1 million shares at HK$14.70–14.90 per share for approximately HK$14.8 million.

    Source:

  • Oct 12, 2026, 00:30 UTC

    3SBio, Inc. repurchased 2.5 million shares at HK$14.98–HK$15.18 per share for approximately HK$37.588 million.

    Source:

  • Oct 9, 2026, 00:47 UTC

    3SBio, Inc. repurchased 1.7 million shares at HK$15.40–HK$15.75 per share for approximately HK$26.5 million.

    Source:

  • Sep 29, 2026, 03:08 UTC

    Hangzhou Derui Zhiyao announced an exclusive commercialization partnership with Zhejiang Sansheng Mandi Pharmaceutical and Wansheng Pharmaceutical for its AI-designed oral small-molecule GLP-1 receptor agonist MDR-001 covering mainland China, Hong Kong and Macau, with a potential total deal value of up to RMB 1.75 billion.

    Source:

  • Aug 20, 2026, 17:16 UTC

    3SBio Inc. announced its interim results for the six months ended June 2026, with net profit of RMB 1.147 billion, down 15.6% year-on-year.

    Source:

  • Jul 21, 2026, 19:36 UTC

    Several Chinese public funds, including E Fund, China Asset Management, Fullgoal Fund, and China Universal Fund, increased their holdings in Hong Kong-listed biotech stocks, triggering the 5% disclosure threshold for Baioct-B, 3SBio, CSPC Pharmaceutical Group, Kelun-Biotech, and H&H International Holdings.

    Source:

  • Jul 3, 2026, 08:52 UTC

    The China National Medical Products Administration's Drug Evaluation Center accepted the marketing authorization application for semaglutide injection (weight loss indication) filed by Sansheng Mandi, a partner of Hybio Pharmaceutical.

    Source: